QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics
Qiagen N.V. Common Shares (QGEN)
Last qiagen n.v. common shares earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corporate.qiagen.com/investor-relations
Company Research
Source: GlobeNewswire
Germantown, Maryland, and Venlo, the Netherlands, Nov. 04, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Meningitis/Encephalitis Panel for clinical use. This marks the fourth QIAstat-Dx syndromic test to receive U.S. regulatory clearance in 2024. Meningitis (inflammation of the membrane surrounding the brain and spinal cord) and encephalitis (inflammation within the brain) are medical emergencies that require immediate treatment. One in five cases of bacterial meningitis results in permanent complications, such as hearing loss, brain damage and seizures and without prompt treatment, about half of patients will die.[1] Bacterial meningitis cases in the United States have reached their highest levels since 2014, with case numbers varying from state to state depending on vaccination rates.[2] Many U.S. healthcare facilities still rely solely on traditi
Show less
Read more
Impact Snapshot
Event Time:
QGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QGEN alerts
High impacting Qiagen N.V. Common Shares news events
Weekly update
A roundup of the hottest topics
QGEN
News
- QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region [Yahoo! Finance]Yahoo! Finance
- QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific RegionBusiness Wire
- Qiagen (NYSE: QGEN) had its price target lowered by analysts at UBS Group AG from $50.00 to $48.00. They now have a "neutral" rating on the stock.MarketBeat
- Qiagen N.V. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]Seeking Alpha
- Qiagen NV (QGEN) Q4 2024 Earnings Report Preview: What To Expect [Yahoo! Finance]Yahoo! Finance
QGEN
Earnings
- 2/5/25 - Beat
QGEN
Sec Filings
- 2/7/25 - Form 6-K
- 2/6/25 - Form SCHEDULE
- 1/16/25 - Form 6-K
- QGEN's page on the SEC website